Eisai received federal approval for its Aciphex Sprinkle delayed-release capsules to address gastroesophageal reflux disease in young children. The therapy is indicated for patients between ages 1 and 11.
Eisai gets FDA nod for pediatric GERD treatment
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||